Celularity (CELU) Stock Price, News & Analysis

Company Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Key Stats

• Today's Range: $1.36 to $1.57
• 50-Day Range: $1.08 to $2.65
• 52-Week Range: $1.00 to $5.69
• Volume: 91,177 shs
• Average Volume: 326,808 shs
• Market Capitalization: $32.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed this year?

Celularity's stock was trading at $2.08 on January 1st, 2025. Since then, CELU shares have decreased by 34.3% and is now trading at $1.3660.
View the best growth stocks for 2025 here.

How were Celularity's earnings last quarter?

Celularity Inc. (NASDAQ:CELU) announced its quarterly earnings data on Friday, December, 6th. The company reported ($0.73) earnings per share for the quarter. Celularity had a negative net margin of 72.72% and a negative trailing twelve-month return on equity of 119.53%.

When did Celularity's stock split?

Celularity's stock reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celularity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 12/06/2024
• Today: 4/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELU
• CIK: 1752828
• Web: www.celularity.com
• Phone: 908-768-2170
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-196,290,000.00
• Net Margins: -72.72%
• Pretax Margin: -72.70%
• Return on Equity: -119.53%
• Return on Assets: -25.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $48.20 million
• Price / Sales: 0.71
• Cash Flow: $5.98 per share
• Price / Cash Flow: 0.24
• Book Value: $2.11 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 23,808,000
• Free Float: 18,546,000
• Market Cap: $34.14 million
• Optionable: Optionable
• Beta: 0.75